Polyrizon (PLRZ) News Today $13.98 +0.27 (+1.97%) Closing price 04:00 PM EasternExtended Trading$13.90 -0.08 (-0.57%) As of 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PLRZ Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2026 April 2026 March 2026 February 2026 January 2026 December 2025 November 2025 October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 Time Period Polyrizon Stock Short Interest Report | NASDAQ:PLRZ | BenzingaMay 16 at 8:24 AM | benzinga.comPolyrizon Secures First U.S. Clinical Site for NASARIX Allergy Blocker TrialMay 13, 2026 | tipranks.comPolyrizon Ltd. Signs Clinical Trial Agreement for NASARIXTM Allergy Blocker Study in TexasMay 13, 2026 | quiverquant.comQPolyrizon Advances Towards Human Clinical Trials: Secures First U.S. Clinical Site for NASARIX™ Allergy Blocker Clinical TrialMay 13, 2026 | globenewswire.comPulse Equity: Emerging Outbreaks - Polyrizon's Approach to Broad and Rapidly Deployable ProtectionMay 11, 2026 | prnewswire.comPolyrizon Expands U.S. Patent Claims for Intranasal Drug Delivery PlatformMay 4, 2026 | tipranks.comPolyrizon Announces U.S. Patent Expansion for Its Intranasal Drug Delivery PlatformMay 4, 2026 | globenewswire.comPolyrizon Ltd. Files Divisional Patent Application for Advanced Trap & Target Intranasal Drug Delivery TechnologyApril 27, 2026 | quiverquant.comQPolyrizon Announces Filing of European Patent Application for Its Breakthrough Drug Delivery PlatformApril 27, 2026 | globenewswire.comPLRZ Share News TodayApril 19, 2026 | uk.investing.comPolyrizon Raises $3.5 Million via Registered Direct Offering and Private PlacementApril 14, 2026 | theglobeandmail.comPolyrizon Ltd. Ordinary Shares (PLRZ) Institutional HoldingsApril 8, 2026 | nasdaq.comPolyrizon Ltd. Completes $3.5 Million Registered Direct Offering and Private PlacementApril 8, 2026 | quiverquant.comQPolyrizon Ltd. Announces Closing of $3.5 Million Registered Direct and Private PlacementsApril 8, 2026 | globenewswire.comPolyrizon Ltd. Announces $3.5 Million Registered Direct Offering and Private PlacementApril 7, 2026 | finance.yahoo.comPolyrizon Ltd. Ordinary Shares (PLRZ) Option ChainMarch 29, 2026 | nasdaq.comPolyrizon Ltd. Ordinary Shares (PLRZ) Insider ActivityMarch 28, 2026 | nasdaq.comPolyrizon Ltd.: Polyrizon Provides 2025 and Recent HighlightsMarch 26, 2026 | finanznachrichten.dePolyrizon Provides 2025 and Recent HighlightsMarch 26, 2026 | globenewswire.comPolyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025March 26, 2026 | markets.businessinsider.comPolyrizon Ltd. Files Annual Report on Form 20-F for Fiscal Year 2025March 25, 2026 | quiverquant.comQPolyrizon Ltd. Signs Non-Binding MOU to Acquire Up to 20% Stake in Colugo Systems Ltd.March 24, 2026 | quiverquant.comQPolyrizon Intends to Acquire up to 20% Stake in Colugo, Developer of Advanced eVTOL Drones for Defense and Urban Air Mobility ApplicationsMarch 24, 2026 | globenewswire.comPolyrizon Ltd.: Polyrizon Signs an Agreement with Leading Global Preclinical CRO as Part of Clinical Development ProgramMarch 17, 2026 | finanznachrichten.dePolyrizon Taps Global CRO to Run Key Preclinical Safety Studies Ahead of First Clinical TrialsMarch 17, 2026 | tipranks.comPolyrizon Signs an Agreement with Leading Global Preclinical CRO as Part of Clinical Development ProgramMarch 17, 2026 | globenewswire.comPolyrizon Ltd.: Polyrizon Announces GMP Manufacturing of Clinical Trial Material (CTM) with Eurofins CDMO AmatsiAquitaine S.A.S for Planned U.S. Clinical StudyMarch 10, 2026 | finanznachrichten.dePolyrizon Completes GMP Clinical Material for Planned U.S. Intranasal StudyMarch 10, 2026 | tipranks.comPolyrizon Ltd. Achieves GMP Production Milestone for Clinical Trial Material Ahead of Planned U.S. StudyMarch 10, 2026 | quiverquant.comQPolyrizon Announces GMP Manufacturing of Clinical Trial Material (CTM) with Eurofins CDMO AmatsiAquitaine S.A.S for Planned U.S. Clinical StudyMarch 10, 2026 | globenewswire.comPolyrizon Ltd. Reports Promising Results in Nasal Deposition Study for Naloxone FormulationFebruary 26, 2026 | quiverquant.comQPolyrizon Announces Successful Study of its Naloxone Formulation Demonstrating Enhanced Nasal Deposition Profile Versus Commercial Reference ProductFebruary 26, 2026 | globenewswire.comMoonage Media Spotlights Polyrizon (Nasdaq: PLRZ): Unveils NASARIX™, Drug-Free Allergy BlockerFebruary 17, 2026 | prnewswire.comPolyrizon stock rises on potential acquisition of Arrow AviationFebruary 10, 2026 | za.investing.comPLRZ stock jumps 6% in pre-market – why is this biotech firm diversifying into aviation business?February 10, 2026 | msn.comPolyrizon Ltd. Signs Non-Binding MOU to Acquire 51% Stake in Arrow Aviation for Strategic Expansion into Private Aviation SectorFebruary 10, 2026 | quiverquant.comQPolyrizon Intends to Secure Controlling Stake in Profitable Private Jet OperatorFebruary 10, 2026 | globenewswire.comPolyrizon climbs on Clearmind DealFebruary 7, 2026 | baystreet.caPolyrizon and Clearmind Partner on Intranasal Non-Hallucinogenic Neuroplastogen MEAIFebruary 6, 2026 | tipranks.comPolyrizon Signs an Agreement to Develop Intranasal Proprietary Non-Hallucinogenic Neuroplastogen FormulationFebruary 6, 2026 | globenewswire.comPolyrizon shares gain on plan to buy majority stake in private aviation companyFebruary 4, 2026 | msn.comPolyrizon stock rises after announcing plan to acquire stake in private aviation firmFebruary 4, 2026 | investing.comPolyrizon Ltd. Announces Non-Binding MOU to Acquire 51% Stake in Arrow AviationFebruary 4, 2026 | quiverquant.comQPolyrizon Intends to Acquire 51% Stake in Global Private Aviation CompanyFebruary 4, 2026 | globenewswire.comPolyrizon Launches FDA-Aligned Usability Study for NASARIX Allergy BlockerJanuary 23, 2026 | theglobeandmail.comPolyrizon Ltd. Initiates Usability Study for NASARIX™ to Advance Clinical Development EffortsJanuary 22, 2026 | quiverquant.comQPolyrizon Advances Regulatory Path with Initiation of Usability Study Program for NASARIX™ Allergy BlockerJanuary 22, 2026 | globenewswire.comPolyrizon Brands PL-14 Intranasal Allergy Blocker as NASARIX™January 13, 2026 | theglobeandmail.comPolyrizon to Explore Revenue-Generating Investment Opportunities in High-Growth Sectors, Leveraging Strong Cash Position and Debt-Free Balance SheetJanuary 13, 2026 | globenewswire.comPolyrizon Ltd. Completes Branding Process for PL-14 Allergy Blocker, Now Named NASARIX™January 8, 2026 | quiverquant.comQ Get Polyrizon News Delivered to You Automatically Sign up to receive the latest news and ratings for PLRZ and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PLRZ Media Mentions By Week PLRZ Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PLRZ News Sentiment▼1.030.39▲Average Medical News Sentiment PLRZ News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PLRZ Articles This Week▼42▲PLRZ Articles Average Week Get the Latest News and Ratings for PLRZ and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Polyrizon and its competitors. Sign Up View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Kalaris Therapeutics News Cognition Therapeutics News Biomea Fusion News Coya Therapeutics News enGene News Aldeyra Therapeutics News Cypherpunk Technologies News Oncolytics Biotech News Q32 Bio News Upexi News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PLRZ) was last updated on 5/19/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Polyrizon Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Polyrizon With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
